CURRENT BOARD NEEDS TO GO, NEW BLOOD NEEDED!

IMO, given the lack of communication and no evidence of a succession plan by this Board, it is clear that Mario and the other two directors are at odds on RSH's future direction.

From his interviews, conference calls and presentations, Mario's strategy was clear and early success in India was key.
I suspect the Chairman and Prof Thompson no longer share this view.

So where is the alternative strategy and plan, how will it be funded, what are the financial implications, how does it create greater shareholder value?

Chairman experience is pokies and Dan Murphy's, Prof Thomas is academic/scientist who hasn't delivered on the studies which was the one thing he was hired to do and he promised results months ago! IMO hardly ideal in commercialising a new MedTech product globally.

Mario at Pfizer for 20 years, launched drugs and medical products globally very successfully, given it was no. 1 pharmaceutical company in the world.
Now that RSH desperately needs these skills and experience, he is the one who goes!! IMO this is madness!!

The action of the current board last week wiped over $10M market capital on the back of this decision and that ridiculous, ambiguous announcement about CEO leaving.

Are we shareholders going to hold them accountable or reward them with keeping their positions and simply move on??

Scapegoating the CEO is classic move for trying to hide own deficiencies and survive.

Must be AGM coming up soon, need to send a clear message that they have to go or say goodbye to our investment.

Apologies for long post. Be very interested in the thoughts of others.